Background:This paper is based on the initial findings from a prospective ongoing study to evaluate the efficacy of flourodeoxy glucose positron emission tomography-computed tomography (FDG-PET CT) in diabetic foot evaluation.Objective:The aim was to compare the diagnostic accuracies of three phase bone scan (TPBS) and FDG PET-CT (FDG-PET) in diabetic foot evaluation.Methods:Seventy-nine patients with complicated diabetic foot (osteomyelitis/cellulitis, Charcot's neuropathy) were prospectively investigated. TPBS (15 mci methylene di phosphonate [MDP] intravenous [IV]), followed by FDG-PET (5 mci IV) within 5 days were performed in all patients. Based on referral indication, patients grouped into Group I, n = 36, (?osteomyelitis/cellulitis) and Group II, n = 43 (?Charcot's neuropathy). Interpretation was based on intensity, extent, pattern of MDP and FDG uptake (standardized uptake value) along with CT correlation. Findings were compared with final diagnostic outcome based on bone/soft tissue culture in Group I and clinical, radiological or scintigraphic followup in Group II. Results: Group I: For diagnosing osteomyelitis, TP: TN: FP: FN were 14:5:2:2 by FDG PET and 13:02:05:03 by TPBS respectively. Sensitivity, specificity, positive predictive value and negative predictive value (NPV) of FDG-PET were 87.5%, 71%, 87.5% and 71% and 81.25%, 28.5%, 72% and 40% for TPBS, respectively. Group II: charcot's: cellulitis: Normal were 22:14:7 by FDG PET and 32:5:6 by TPBS, respectively.Conclusion:Flourodeoxy glucose PET-CT has a higher specificity and NPV than TPBS in diagnosing pedal osteomyelitis. TPBS, being highly sensitive is more useful than FDG-PET in detecting Charcot's neuropathy.
Radiofrequency
ablation (RFA) and doxorubicin (Dox) chemotherapy
are separately approved for liver cancer therapy; however, both have
limited success in the clinic due to suboptimal/nonuniform heating
and systemic side effects, respectively. Here, we report a biodegradable
nanoparticle (NP) system showing excellent RF hyperthermic response
together with the ability to locally deliver Dox in the liver under
RF trigger and control. The nanosystem was prepared by doping a clinically
permissible dose (∼4.3 wt %, 0.03 ppm) of stannous ions in
alginate nanoparticles (∼100 nm) coloaded with Dox at ∼13.4
wt % concentration and surface conjugated with galactose for targeting
asialo-glycoprotein receptors in liver tumors. Targeted NP-uptake
and increased cytotoxicity when combined with RF exposure was demonstrated
in HEPG2 liver cancer cells. Following in vitro (chicken liver phantom)
demonstration of locally augmented RF thermal response, in vivo scintigraphic
imaging of 99Tc-labeled NPs was performed to optimize liver
localization in Sprague–Dawley (SD) rats. RF ablation was performed
in vivo using a cooled-tip probe, and uniformly enhanced (∼44%)
thermal ablation was demonstrated with magnetic resonance imaging
along with RF-controlled Dox release. In orthotopic rat liver tumor
models, real-time infrared imaging revealed significantly higher (∼20
°C) RF thermal response at the tumor site, resulting in uniform
augmented ablation (∼80%) even at a low RF power exposure of
15 W for just 1 min duration. Being a clinically acceptable, biodegradable
material, alginate nanoparticles hold strong translational potential
for augmented RF hyperthermia combined with triggered drug release.
Antegrade pulmonary aspiration can be demonstrated as an underlying cause for persistent/recurrent lower respiratory tract infection in developmentally normal children, with age being an important clinical predictor. Combined use of salivagram and milk scan is warranted to objectively evaluate pulmonary aspiration in children.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.